A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.

Sarcoidosis Vasc Diffuse Lung Dis · 2020 · PMC7569556 · PMID 33093778

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In case, a patient does not opt for or tolerate nintedanib, one can still administer a lower dose of pirfenidone as the survival in the reduced-dose group also showed a trend towards improvement in our study (though statistically non-significant).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.